Literature DB >> 17113687

Suppression of diabetes in non-obese diabetic (NOD) mice by oral administration of a cholera toxin B subunit-insulin B chain fusion protein vaccine produced in silkworm.

Zhaohui Gong1, Yongfeng Jin, Yaozhou Zhang.   

Abstract

Oral tolerance has been applied successfully as a potential therapeutic strategy for preventing and treating autoimmune diseases including type 1 diabetes. In this paper we constructed an edible vaccine consisting of a fusion protein composed of cholera toxin B subunit (CTB) and insulin B chain (InsB) that was produced in silkworm larvae. The silkworm larvae produced this fusion protein at levels of up to 0.97mg/ml of hemolymph as the pentameric CTB-InsB form, which retained the GM1-ganglioside binding affinity and the native antigenicity of CTB. Non-obese diabetic mice fed hemolymph containing microgram quantities of the CTB-InsB fusion protein showed a prominent reduction in pancreatic islet inflammation and a delay in the development of diabetic symptoms. This study demonstrates that silkworm-produced CTB-InsB fusion protein can be used as an ideal oral protein vaccine for induction of immunological tolerance against autoimmune diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17113687     DOI: 10.1016/j.vaccine.2006.10.039

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Cholera toxin B subunit linked to glutamic acid decarboxylase suppresses dendritic cell maturation and function.

Authors:  Oludare Odumosu; Dequina Nicholas; Kimberly Payne; William Langridge
Journal:  Vaccine       Date:  2011-07-30       Impact factor: 3.641

Review 2.  Biotransformation effect of Bombyx Mori L. may play an important role in treating diabetic nephropathy.

Authors:  Lei Zhang; Yin Li; Xin-Feng Guo; Xu-Sheng Liu
Journal:  Chin J Integr Med       Date:  2015-12-19       Impact factor: 1.978

3.  Suppression of dendritic cell activation by diabetes autoantigens linked to the cholera toxin B subunit.

Authors:  Oludare Odumosu; Kimberly Payne; Ineavely Baez; Jessica Jutzy; Nathan Wall; William Langridge
Journal:  Immunobiology       Date:  2010-09-24       Impact factor: 3.144

Review 4.  Current advances and future prospects in production of recombinant insulin and other proteins to treat diabetes mellitus.

Authors:  Sapna Bhoria; Jyoti Yadav; Honey Yadav; Darshna Chaudhary; Ranjana Jaiwal; Pawan K Jaiwal
Journal:  Biotechnol Lett       Date:  2022-04-17       Impact factor: 2.461

5.  In vivo bioassay of recombinant human growth hormone synthesized in B. mori pupae.

Authors:  Hanglian Lan; Zuoming Nie; Yue Liu; Zhengbing Lv; Yingshuo Liu; Yanping Quan; Jianqing Chen; Qingliang Zhen; Qin Chen; Dan Wang; Qing Sheng; Wei Yu; Jian Chen; Xiangfu Wu; Yaozhou Zhang
Journal:  J Biomed Biotechnol       Date:  2010-03-18

6.  Expression of a ricin toxin B subunit: insulin fusion protein in edible plant tissues.

Authors:  James E Carter; Oludare Odumosu; William H R Langridge
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

7.  Cholera toxin subunit B peptide fusion proteins reveal impaired oral tolerance induction in diabetes-prone but not in diabetes-resistant mice.

Authors:  Maximiliano Presa; Angela Zarama Ortiz; Nahir Garabatos; Cristina Izquierdo; Elisa I Rivas; Luc Teyton; Conchi Mora; David Serreze; Thomas Stratmann
Journal:  Eur J Immunol       Date:  2013-08-27       Impact factor: 5.532

Review 8.  Cholera Toxin Subunit B as Adjuvant--An Accelerator in Protective Immunity and a Break in Autoimmunity.

Authors:  Thomas Stratmann
Journal:  Vaccines (Basel)       Date:  2015-07-24

9.  Oral Administration of Silkworm-Produced GAD65 and Insulin Bi-Autoantigens against Type 1 Diabetes.

Authors:  Baoping Liu; Yuan Yue; Yun Yang; Yongfeng Jin
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

10.  Production of Pentameric Cholera Toxin B Subunit in Escherichia coli.

Authors:  Farida Dakterzada; Ashraf Mohabati Mobarez; Mehryar Habibi Roudkenar; Mehdi Forouzandeh
Journal:  Avicenna J Med Biotechnol       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.